According to our latest study on “High Potency APIs Market Forecast to 2028 — COVID-19 Impact and Global Analysis — by Type, Type of Synthesis, Manufacturer, Therapeutic Application, and Geography,” the market is expected to grow from US$ 22.74 billion in 2021 to US$ 42.65 billion by 2028; it is estimated to grow at a CAGR of 9.4% from 2022 to 2028.

The report presents the market competitive landscape and consistent in-depth analysis of the major vendor/key players in the market along with the impact of economic slowdown due to COVID.

Receive Additional Statistics on “High Potency APIs Market”: https://www.theinsightpartners.com/sample/TIPRE00003533/

According to the WHO, cancer is the leading cause of death, accounting for over 10 million deaths in 2020. As per the CDC, risk factors such as smoking, obesity, alcohol consumption, and exposure to UV radiation from the sun and tanning beds have contributed to the disease’s overall burden. Due to the rising prevalence of cancer, there is a high demand for potent cancer therapeutics, including HPAPIs. To meet the rising demand, Pfizer, Sanofi, F. Hoffmann-La Roche, and other pharmaceutical companies are developing novel cancer therapeutics. Therefore, the rising cancer prevalence is expected to drive the market for High Potency APIs (HPAPI).

Pfizer Inc, F Hoffmann La Roche Ltd, Eli Lilly and Company, Bristol Myers Squibb Company, Novartis AG, Sanofi, Merck Sharp and Dohme Corp, Bayer AG, AbbVie, and Teva Pharmaceutical Industries Ltd. are a few of the key players profiled in the study of the high potency APIs market. Several other major companies were analyzed during this study to get a holistic view of the market and its ecosystem.

Based on type of synthesis, the high potency APIs market is bifurcated into synthetic and biotech. In 2021, the synthetic segment held a larger market share. The market growth for the synthetic segment is driven by an increase in the number of novel APIs, drug approvals, and ease of production.

Based on manufacturer, the high potency APIs market is bifurcated into in-house and outsourced. In 2021, the in-house segment accounted for a larger market share owing to large volume produced via companies in-house manufacturing facilities.

Based on therapeutic application, the high potency APIs market is segmented into oncology, hormonal imbalance, glaucoma, and others. In 2021, the oncology segment dominated the market due to the rising prevalence of cancer and the introduction of novel drugs.

To comprehend global High Potency APIss market dynamics in the world mainly, the worldwide market is analyzed across major global regions: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Healthcare, Manufacturing and Construction, Media and Technology, Chemicals, and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1–646–491–9876